Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930015 | 0.83 | HASPIN (0.35) | HASPINADRA1DADRA1AADRA1B | |
| SCHEMBL4348692 | 0.82 | ADRA1D (0.37) | ADRA1DADRA1AADRA1B | |
| SCHEMBL17371770 | 0.80 | HASPIN (0.43) | HASPINADRA1DADRA1AADRA1BHPGD | |
| SCHEMBL5792155 | 0.79 | MMP2 (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL3235865 | 0.79 | ADRA1D (0.37) | HASPINADRA1DADRA1AADRA1B | |
| SCHEMBL338056 | 0.78 | TYMP (0.32) | ADRA1DADRA1AADRA1B | |
| SCHEMBL8377755 | 0.78 | TYMP (0.32) | ADRA1DADRA1AADRA1B | |
| SCHEMBL8377767 | 0.78 | ADRA1D (0.31) | ADRA1DADRA1AADRA1B | |
| SCHEMBL1923337 | 0.78 | CYP1A2 (0.44) | ALDH1A1CYP3A4 | |
| SCHEMBL10618040 | 0.78 | ADRA1D (0.33) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | claimed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | claimed |
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250382612-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC FUS VARIANTS | THE PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCE LIMITED (AU) | 2025-12-18 | — | — | US | disclosed |
| US-12234448-B2 | Purification of nucleic acids using titanium oxides | ABBOTT MOLECULAR INC. | 2025-02-25 | — | — | US | disclosed |
| US-20230193240-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2023-06-22 | — | — | US | disclosed |
| US-11608496-B2 | Purification of nucleic acids using copper-titanium oxides | ABBOTT MOLECULAR INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220242924-A1 | C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3988658-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | Abbott Molecular Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11313001-B2 | Compositions and methods for detection of microorganisms | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| WO-1999026960-A2 | GENES ENCODING FRIZZLED-LIKE PROTEINS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999024610-A1 | NOVEL GENES ENCODING TRANSPORTER-LIKE MOLECULES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999007850-A1 | TANGO-71, TANGO-73, TANGO-74, TANGO-76, AND TANGO-83 NUCLEIC ACID MOLECULES AND POLYPEPTIDES | MILLENNIUM BIOTHERAPEUTICS, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999002545-A2 | ANTIGEN BINDING FRAGMENTS, DESIGNATED 4B5, THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS | NOVOPHARM BIOTECH INC. (CA) | 1999-01-21 | — | — | WO | disclosed |
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | C5AR2, C3AR1, CFD | HASPIN 1791/4885ADRA1D 4041/4885ADRA1A 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.